| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process.
Lisata's investigational product, certepetide, to be the subject of a comprehensive AI-analysis to determine optimum disease targets and development strategies.
GATC to leverage Lisata's experience and operational excellence in translational medicine and drug development to advance their drug candidate pipeline products into clinical trials.
Posted In: LSTA
